Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidum
- Development stage
- Unknown
- Lead developer
- Vector-BiAlgam
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidum is a liquid probiotic concentrate containing live *Bifidobacterium bifidum* (specifically the strain 791/BAG), developed and manufactured by the Russian biotechnology company Vector-BiAlgam. The product is designed to restore and maintain the balance of intestinal microflora, which can be disrupted by factors such as antibiotic therapy, infections, or poor diet. As a live biotherapeutic, it works by colonizing the gastrointestinal tract, competing with pathogenic microorganisms for nutrients and adhesion sites, and producing metabolites like lactic and acetic acids that lower luminal pH. Bifidum is marketed in Russia for the treatment and prevention of dysbiosis, gastrointestinal disorders, and as an adjunct therapy for various infectious diseases to support the immune system.
- Brand names
- Bifidum
- Other names
- BifidumbacterinBifidumbacterin liquidBifidobacterium bifidum 791/BAG
Beyond the preview
Go deeper on Bifidum.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidum.